Ogston KN,
Miller ID,
Payne S,
Hutcheon AW,
Sarkar TK,
Smith I,
Schofield A,
Heys SD.
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Breast 2003;12:320-7.
Chagpar AB, Middleton LP,
Sahin AA,
Dempsey P,
Buzdar AU,
Mirza AN,
Ames FC, Babiera,
GV,
Feig BV, Hunt KK,
Kuerer HM, Meric-Bernstam F,
Ross MI, Singletary SE,
Accuracy of Physical Examination,
Ultrasonography,
and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy.
Ann Surg 243;2006:257-64.
Partridge SC,
Gibbs JE,
Lu Y,
Esserman LJ,
Sudilovsky D,
Hylton NM.
Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
AJR Am J Roentgenol 2002;179:1193–1199.
Fangberget A,
Nilsen LB,
Hole KH,
Holmen MM! Engebraaten O,
Naume B,
Smith HJ, OlsenDR, Seierstad T.
Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment
using dynamic contrast-enhanced and diffusion-weighted MR imaging.
Eur Radiol 2011;21:1188-99.
Uematsu T, Kasami M, Yuen S.
Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy.
Eur Radiol 2010;20:2315-22.
Sahoo S,
Lester SC.
Pathology of Breast Carcinomas After Neoadjuvant Chemotherapy.
An Overview With Recommendations on Specimen Processing and Reporting.
Arch Pathol Lab Med 2009;133:633-42.
Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M,
Gautam S,Hatabu H, Kan S,
Mountford C.
Identification of Residual
Breast Carcinoma Following Neoadjuvant Chemotherapy: Diffusion-weighted Imaging.
Comparison with Contrast-enhanced MR Imaging and Pathologic Findings.
Radiology 2010;254:357-66.
El Khoury C,
Servois V,
Thibault F,
et al.
MR quantification of the washout changes in breast tumors under preoperative chemo- therapy: feasibility and preliminary results.
AJR Am J Roentgenol 2005;184:1499–1504